Key facts
- Ancilia Bio’s last known valuation is $28.0M (Apr 2026).
- It has raised $11.1M across 1 recorded rounds; the latest was Early Stage VC in Apr 2023.
- Notable investors include US National Science Foundation, Metaplanet Holdings, National Institutes of Health, New York Ventures, Spacecadet Ventures — 13 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Ancilia Bio
Funding rounds
1 roundsAbout Ancilia Bio
Developer of virus-resistant live bacterial products designed to modulate the human microbiome. The company targets the viral components of the gut microbiome to treat disease and focuses on healthy gut bacteria and their predatory phages to engineer resistant strains, and also develops a new class of live biotherapeutics, enabling medical science professionals to specifically target phages or viruses with a specific affinity for inducing lysis.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2019
- Employees
- 5
- Website
- anciliabio.com/
- Ownership
- Privately Held (backing)
Ancilia Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ancilia Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ancilia Bio in its N-PORT filings yet. We sweep new filings monthly.